Evidence map›Paper›PMID 34125374›Full record

Trial reportJournal of neuro-oncology2021

A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.

Nancy Ann Oberheim Bush, Jacob S Young, Yalan Zhang, Cecilia L Dalle Ore, Annette M Molinaro, Jennie Taylor, Jennifer Clarke, Michael Prados, Steve E Braunstein, David R Raleigh and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nancy Ann Oberheim Bush *Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Jacob S Young *Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Yalan ZhangDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Cecilia L Dalle OreDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Jennie TaylorDivision of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Jennifer ClarkeDivision of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Michael PradosDivision of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Steve E BraunsteinDepartment of Radiation Oncology, University of California, San Francisco, CA, USA.
David R RaleighDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Susan M ChangDepartment of Neurology, University of California, San Francisco, CA, USA.
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Nicholas A ButowskiDivision of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, CA, USA. butowski@neurosurg.ucsf.edu.ORCID http://orcid.org/0000-0001-5162-2406

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion. There is no curative therapy, and standard of care includes surgical resection followed by radiation and chemotherapy. However, the benefit of up-front radiation with chemotherapy compared to chemotherapy alone has not been demonstrated in a randomized control trial. Given the potential long-term consequences of radiation therapy, such as cognitive impairment, arteriopathy, endocrinopathy, and hearing/visual impairment, there is an effort to balance longevity with radiation toxicity.

methodsWe performed a retrospective single institution analysis of survival of patients with anaplastic oligodendroglioma over 20 years.

results159 patients were identified as diagnosed with an anaplastic oligodendroglioma between 1996 and 2016. Of those, 40 patients were found to have AO at original diagnosis and had documented 1p19q co-deletion with a median of 7.1 years of follow-up (range: 0.6-16.7 years). After surgery, 45 % of patients were treated with radiation and chemotherapy at diagnosis, and 50 % were treated with adjuvant chemotherapy alone. The group treated with chemotherapy alone had a trend of receiving more cycles of chemotherapy than patients treated with radiation and chemotherapy upfront (p = 0.051). Median overall survival has not yet been reached. The related risk of progression in the upfront, adjuvant chemotherapy only group was almost 5-fold higher than the patients who received radiation and chemotherapy (hazard ratio = 4.85 (1.74-13.49), p = 0.002). However, there was no significant difference in overall survival in patients treated with upfront chemotherapy compared to patients treated upfront with chemotherapy and radiation (p = 0.8). Univariate analysis of age, KPS, extent of resection, or upfront versus delayed radiation was not associated with improved survival.

conclusionsInitial treatment with adjuvant chemotherapy alone, rather than radiation and chemotherapy, may be an option for some patients with anaplastic oligodendroglioma, as it is associated with similar overall survival despite shorter progression free survival.

Indexed as

Brain NeoplasmsOligodendrogliomaAstrocytomaHumansRetrospective StudiesAnaplastic OligodendrogliomaChemotherapyGliomaRadiation

Identifiers

PMID34125374
PMCPMC8279971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.